Get started
Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ACRS chart


Full chart

ACRS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪282.87 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.52 USD
Net income (FY)
‪−88.48 M‬ USD
Revenue (FY)
‪31.25 M‬ USD
Shares float
‪68.57 M‬
Beta (1Y)
0.73

Employees


Employees (FY)
91
Change (1Y)
−14 −13.33%
Revenue / Employee (1Y)
‪343.40 K‬ USD
Net income / Employee (1Y)
‪−972.32 K‬ USD

About Aclaris Therapeutics, Inc.


Sector
Health Technology
CEO
Neal S. Walker
Headquarters
Wayne
Website
aclaristx.com
Founded
2012
FIGI
BBG003LF0QR9
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ACRS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ACRS is 4.20 USD — it has decreased by −13.73% in the past 24 hours. Watch Aclaris Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aclaris Therapeutics, Inc. stocks are traded under the ticker ACRS.
ACRS stock has risen by 55.29% compared to the previous week, the month change is a 232.77% rise, over the last year Aclaris Therapeutics, Inc. has showed a 366.11% increase.
We've gathered analysts' opinions on Aclaris Therapeutics, Inc. future price: according to them, ACRS price has a max estimate of 13.00 USD and a min estimate of 3.00 USD. Watch ACRS chart and read a more detailed Aclaris Therapeutics, Inc. stock forecast: see what analysts think of Aclaris Therapeutics, Inc. and suggest that you do with its stocks.
ACRS reached its all-time high on Dec 17, 2015 with the price of 33.88 USD, and its all-time low was 0.59 USD and was reached on Nov 13, 2023. View more price dynamics on ACRS chart.
See other stocks reaching their highest and lowest prices.
ACRS stock is 14.50% volatile and has beta coefficient of 0.73. Track Aclaris Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aclaris Therapeutics, Inc. there?
Today Aclaris Therapeutics, Inc. has the market capitalization of ‪282.87 M‬, it has increased by 81.65% over the last week.
Yes, you can track Aclaris Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aclaris Therapeutics, Inc. is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
ACRS earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.01 USD resulting in a ‪−1.83 K‬% surprise. The estimated earnings for the next quarter are −0.25 USD per share. See more details about Aclaris Therapeutics, Inc. earnings.
Aclaris Therapeutics, Inc. revenue for the last quarter amounts to ‪4.35 M‬ USD, despite the estimated figure of ‪1.57 M‬ USD. In the next quarter, revenue is expected to reach ‪2.24 M‬ USD.
ACRS net income for the last quarter is ‪−7.59 M‬ USD, while the quarter before that showed ‪−10.99 M‬ USD of net income which accounts for 30.95% change. Track more Aclaris Therapeutics, Inc. financial stats to get the full picture.
No, ACRS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 91.00 employees. See our rating of the largest employees — is Aclaris Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aclaris Therapeutics, Inc. EBITDA is ‪−55.58 M‬ USD, and current EBITDA margin is −363.74%. See more stats in Aclaris Therapeutics, Inc. financial statements.
Like other stocks, ACRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aclaris Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aclaris Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aclaris Therapeutics, Inc. stock shows the buy signal. See more of Aclaris Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.